ABG
WHWK

Ally Bridge Group’s Whitehawk Therapeutics WHWK Stock Holding History

Ally Bridge Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.82M Hold
817,939
– – 2.28% 22
2025
Q4 		$1.98M Hold
817,939
– – 2.06% 17
2025
Q3 		$1.55M Hold
817,939
– – 0.95% 22
2025
Q2 		$1.53M Hold
817,939
– – 1.27% 21
2025
Q1 		$1.46M Hold
817,939
– – 1.31% 24
2024
Q4 		$2.58M Buy
+817,939
New +$1.85M 2.21% 20
2023
Q1 		– Sell
-632,997
Closed -$8.12M – 39
2022
Q4 		$8.12M Buy
632,997
+508,372
+408% +$6.64M 7.9% 2
2022
Q3 		$1.76M Buy
+124,625
New +$1.64M 1.16% 27

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Ally Bridge Group's WHWK Position: Q1 2026 in Review

Ally Bridge Group held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 817,939 shares worth $2.82M. The position accounts for 2.28% of the portfolio, ranked #22.

Ally Bridge Group first reported a position in WHWK in Q3 2022 and has held it in 8 quarters since. The position peaked at $8.12M in Q4 2022. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Ally Bridge Group held 817,939 shares of Whitehawk Therapeutics worth $2.82M as of Q1 2026.
  • Ally Bridge Group left its Whitehawk Therapeutics share count unchanged in Q1 2026.
  • Whitehawk Therapeutics made up 2.28% of Ally Bridge Group's portfolio in Q1 2026, its #22 holding.
  • Ally Bridge Group first reported a position in Whitehawk Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • Ally Bridge Group's Whitehawk Therapeutics position peaked at $8.12M in Q4 2022.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.